伴微血管炎症的临界性与T细胞介导排斥反应的肾移植结局
本研究纳入1614例首次活检证实的纯TCMR受者,按MVI有无分组,用RMST分析移植肾存活。结果显示TCMR+MVI全因移植物丢失风险更高(HR 1.57),5年RMST最低,且合并v病变时风险达2.77倍。
要点
- 纯TCMR合并MVI者移植物丢失风险显著升高(HR 1.57)
- 亚阈值MVI未增加移植物丢失风险
- TCMR+MVI合并v病变者风险高达2.77倍
核心结论
- 纯TCMR伴MVI是移植肾存活更差的高危表型,合并v病变时风险尤为显著。
研究设计与样本
- 回顾性队列研究,纳入2010-2023年1614例首次活检证实的纯TCMR受者,按MVI有无分组,采用限制性平均生存时间分析移植肾存活。
主要发现
- 85%无MVI,8%为亚阈值MVI(g+ptc=1),7%为MVI(g+ptc≥2)。
- TCMR+MVI较无MVI的全因移植物丢失风险更高(HR 1.57,95%CI 1.06-2.34)。
- 亚阈值MVI未与移植物丢失风险增加相关。
- 5年RMST在MVI组最低(3.93年,95%CI 3.53-4.26),亚阈值组为4.39年(95%CI 4.11-4.60),无MVI组为4.32年(95%CI 4.24-4.40)。
- TCMR+MVI合并v病变者移植物丢失风险为2.77倍(95%CI 1.64-4.67),无血管病变者未见超额风险。
关键数值与推荐
- MVI定义为Banff g+ptc≥2,亚阈值MVI定义为g+ptc=1。
- v病变阳性定义为活检存在血管病变。
临床怎么用
- 对纯TCMR伴MVI(尤其合并v病变)的受者应识别为高危人群,加强移植肾存活监测。
局限性
- 原文未报告研究设计的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Microvascular inflammation (MVI) is a hallmark feature of antibody-mediated rejection (ABMR), but its prognostic significance when it occurs with T-cell-mediated rejection (TCMR) in the absence of other ABMR features remains unclear. METHODS: We examined the association between pure TCMR phenotypes, defined by the presence or absence of MVI, and graft survival using restricted mean survival time (RMST), and assessed interactions with rejection involving a "v" lesion. RESULTS: Among 1614 recipients with first biopsy-proven pure TCMR (2010-2023), 85% had no MVI, 8% subthreshold MVI (Banff glomerulitis [g] + peritubular capillaritis [ptc] = 1), and 7% with MVI (g + ptc ≥ 2). Compared with TCMR without MVI, recipients with TCMR + MVI (hazard ratio [HR]; 95% confidence intervals [CI] 1.57 [1.06-2.34]) had a higher risk of all-cause graft loss, whereas subthreshold MVI was not associated with increased risk. The 5-year RMST was lowest in the MVI group (3.93 [3.53-4.26]), compared with the subthreshold group (4.39 [4.11- 4.60]) and the no MVI group (4.32 [4.24-4.40]). Rejection with a "v" lesion modified this association. Recipients with TCMR + MVI and positive "v" lesion had a 2.77-fold higher risk of graft loss (2.77 [1.64-4.67]), whereas no excess risk was observed in those without vascular lesions. CONCLUSION: Pure TCMR with MVI, particularly in the setting of a "v" lesion, represents a high-risk phenotype associated with poorer graft survival, warranting mechanistic investigations and targeted therapeutic strategies.
引用
- Lim WH, Wang J, Teixeira-Pinto A, et al. Kidney Allograft Outcomes in Borderline and T Cell-Mediated Rejection With Microvascular Inflammation. Kidney Int Rep. 2026. PMID: 42666913. doi:10.1016/j.ekir.2026.106707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。